Rising burden of superficial fungal infections in India and the role of Clotrimazole for optimal management

---

Review Article

Author Details : Shashank Bhargava, Siddhartha Chakrabarty, Rajan T Damodaran, Prasanna Kumar Saikia, Manjunath Shenoy, Nikhil Bangale, Poonam Shah*

Volume : 9, Issue : 1, Year : 2023

Article Page : 1-16

https://doi.org/10.18231/j.ijced.2023.001

Suggest article by email

Get Permission

---

Abstract

Cutaneous dermatophytosis are among the most common infections seen in clinical practice. Over the past few years there has been a rising trend in the prevalence with change in spectrum of infection and isolation of some uncommon species. Recognition and appropriate treatment of these infections is important to reduce the morbidity and discomfort and also reduce the possibility of transmission. Azoles are the antifungal agents used extensively to treat dermatophytosis. Clotrimazole is mainly used locally in the treatment of skin fungal infections due to dermatophytes and yeasts. It is known to provide a broad-spectrum antifungal coverage against dermatophytes, moulds, yeasts and some bacteria, and is an efficient, safe and well accepted treatment for skin fungal infections in children and adults. This review provides an overview of the role of topical clotrimazole available as cream and powder and in combination with topical steroid for the optimal management of skin fungal infections.
 

Keywords: Dermatophytosis, Superficial fungal infection, Tinea infections, Topical therapy, Antifungal agents, Clotrimazole

How to cite : Bhargava S, Chakrabarty S, Damodaran R T, Saikia P K, Shenoy M, Bangale N, Shah P, Rising burden of superficial fungal infections in India and the role of Clotrimazole for optimal management. IP Indian J Clin Exp Dermatol 2023;9(1):1-16

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.